Engaging With Patients Early and Often

When developing new therapies, pharmaceutical companies should be engaging with patients long before clinical trials are started. Andy Pyfer, partner at Fingerpaint, delves into the importance of involving patients early on in the process, and how all members of a company should be thinking about the patient in the work that they are doing.

Pyfer told PharmaVOICE, “The patient should influence everyone from bench scientists and the human resources team to the finance department and engineers designing the product’s packaging.” He further highlighted how the rare disease space is leveraging the information and knowledge that patients have, and how companies are “tapping them to guide their decisions.”